J Figueras1, C Peña, J Soler-Soler. 1. Unitat Coronària, Servei de Cardiologia, Hospital General Universitari d'Hebron, Universitat Autònoma de Barcelona, P Vall d'Hebron 119-129, 08035 Barcelona, Spain. 5751jfb@comb.es
Abstract
OBJECTIVES: To investigate the characteristics of the acute coronary syndromes underlying acute pulmonary oedema and their 30 day prognosis. PATIENTS: 185 consecutive patients with acute coronary syndromes and acute pulmonary oedema admitted to a tertiary care centre. MAIN OUTCOME AND MEASURES: Clinical, ECG, echocardiographic, enzymatic, and angiographic features were prospectively investigated. RESULTS: Non-ST segment elevation myocardial infarction (NSTEMI) was the most frequent cause of acute pulmonary oedema (61%) followed by unstable angina (UA; 21%) and ST segment elevation myocardial infarction (STEMI; 18%). In each group, mean age was > or = 70 years, but NSTEMI patients were the oldest and > or = 65% of patients had chronic hypertension. Moreover, patients with NSTEMI and UA were older and had a higher incidence of diabetes, previous myocardial infarction, and moderate to severe mitral regurgitation but a similarly reduced ejection fraction (NSTEMI, 41%; UA, 39%; and STEMI, 39%) and increased incidence of diastolic dysfunction and rate of multivessel disease (94%, 87%, and 86%, respectively). However, patients with STEMI had a higher creatine kinase MB peak concentration (158 v 76 microg/l in the NSTEMI group, p < 0.001) and 30 day mortality (26% v 9% in the NSTEMI group and 8% in the UA group, p < 0.024). Multivariate analysis identified ejection fraction < 40% and a peak creatine kinase MB concentration > 100 microg/l as the main prognostic markers (p < 0.03). CONCLUSIONS: Acute pulmonary oedema is mostly a complication of elderly hypertensive patients with NSTEMI or UA (82%) and with multivessel disease often associated with mitral regurgitation. On the other hand, the larger infarct size and higher mortality in patients with STEMI with a similarly reduced ejection fraction suggest a more extensive acute systolic loss.
OBJECTIVES: To investigate the characteristics of the acute coronary syndromes underlying acute pulmonary oedema and their 30 day prognosis. PATIENTS: 185 consecutive patients with acute coronary syndromes and acute pulmonary oedema admitted to a tertiary care centre. MAIN OUTCOME AND MEASURES: Clinical, ECG, echocardiographic, enzymatic, and angiographic features were prospectively investigated. RESULTS: Non-ST segment elevation myocardial infarction (NSTEMI) was the most frequent cause of acute pulmonary oedema (61%) followed by unstable angina (UA; 21%) and ST segment elevation myocardial infarction (STEMI; 18%). In each group, mean age was > or = 70 years, but NSTEMI patients were the oldest and > or = 65% of patients had chronic hypertension. Moreover, patients with NSTEMI and UA were older and had a higher incidence of diabetes, previous myocardial infarction, and moderate to severe mitral regurgitation but a similarly reduced ejection fraction (NSTEMI, 41%; UA, 39%; and STEMI, 39%) and increased incidence of diastolic dysfunction and rate of multivessel disease (94%, 87%, and 86%, respectively). However, patients with STEMI had a higher creatine kinase MB peak concentration (158 v 76 microg/l in the NSTEMI group, p < 0.001) and 30 day mortality (26% v 9% in the NSTEMI group and 8% in the UA group, p < 0.024). Multivariate analysis identified ejection fraction < 40% and a peak creatine kinase MB concentration > 100 microg/l as the main prognostic markers (p < 0.03). CONCLUSIONS:Acute pulmonary oedema is mostly a complication of elderly hypertensivepatients with NSTEMI or UA (82%) and with multivessel disease often associated with mitral regurgitation. On the other hand, the larger infarct size and higher mortality in patients with STEMI with a similarly reduced ejection fraction suggest a more extensive acute systolic loss.
Authors: F Van De Werf; J Adgey; D Ardissino; P W Armstrong; P Aylward; G Barbash; A Betriu; A S Binbrek; R Califf; R Diaz; R Fanebust; K Fox; C Granger; J Heikkilä; S Husted; P Jansky; A Langer; E Lupi; A Maseri; J Meyer; J Mlczoch; D Mocceti; D Myburgh; A Oto; E Paolasso; K Pehrsson; R Seabra-Gomes; L Soares-Piegas; D Sùgrue; M Tendera; E Topol; P Toutouzas; A Vahanian; F Verheugt; L Wallentin; H White Journal: Lancet Date: 1999-08-28 Impact factor: 79.321
Authors: G Rioufol; G Finet; I Ginon; X André-Fouët; R Rossi; E Vialle; E Desjoyaux; G Convert; J F Huret; A Tabib Journal: Circulation Date: 2002-08-13 Impact factor: 29.690
Authors: Jaume Figueras; Alberto Juncal; Josefa Cortadellas; José A Barrabés; Jordi Soler Soler Journal: Int J Cardiol Date: 2004-04 Impact factor: 4.164
Authors: K L Lee; L H Woodlief; E J Topol; W D Weaver; A Betriu; J Col; M Simoons; P Aylward; F Van de Werf; R M Califf Journal: Circulation Date: 1995-03-15 Impact factor: 29.690
Authors: Artur Dziewierz; Dawid Giszterowicz; Zbigniew Siudak; Tomasz Rakowski; Jacek S Dubiel; Dariusz Dudek Journal: Clin Res Cardiol Date: 2010-05-11 Impact factor: 5.460